PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P826PC00	**FOR FURTHER ACTION**	See Form PCT/IPEA/416
International application No. PCT/DK2005/000065	International filing date *(day/month/year)* 28.01.2005	Priority date *(day/month/year)* 30.01.2004
International Patent Classification (IPC) or national classification and IPC INV. A61K7/48		
Applicant ACE APS et al		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. ☒ *sent to the applicant and to the International Bureau)* a total of 11 sheets, as follows:
      ☒ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      ☒ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
   b. ☐ *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

- ☒ Box No. I Basis of the report
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

Date of submission of the demand	Date of completion of this report
29.11.2005	11.08.2006
Name and mailing address of the international preliminary examining authority: European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized officer Sierra Gonzalez, M Telephone No. +31 70 340-3751

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/DK2005/000065

Box No. I Basis of the report

1. With regard to the **language**, this report is based on

☒ the international application in the language in which it was filed

☐ a translation of the international application into , which is the language of a translation furnished for the purposes of:

- ☐ international search (under Rules 12.3(a) and 23.1(b))
- ☐ publication of the international application (under Rule 12.4(a))
- ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))

2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages

1-38 as originally filed

Claims, Numbers

1-22 received on 16.06.2006 with letter of 16.06.2006

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing

3. ☒ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☒ the claims, Nos. 1-48
- ☐ the drawings, sheets/figs
- ☐ the sequence listing *(specify)*:
- ☐ any table(s) related to sequence listing *(specify)*:

4. ☒ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages
- ☒ the claims, Nos. 1-56
- ☐ the drawings, sheets/figs
- ☐ the sequence listing *(specify)*:
- ☐ any table(s) related to sequence listing *(specify)*:

* *If item 4 applies, some or all of these sheets may be marked "superseded."*

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/DK2005/000065

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	5-11, 20
	No:	Claims	1-4 12-19 21-22
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-22
Industrial applicability (IA)	Yes:	Claims	1-22
	No:	Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Re Item I.

The amendments filed with the letter dated 25.11.2005 introduce subject-matter which extends beyond the content of the application as filed, contrary to Article 34(2)(b) PCT. The amendments concerned are the following expression: "with the proviso that if said method if for the prevention of photoageing, then said ACE inhibitor is not captopril". Such a disclaimer has not been disclosed in the application as originally filed and the subject-matter there disclosed cannot be considered "accidental anticipation". For a subject-matter to be considered "accidental anticipation", it should be known for a completely different use, and therefore, only properties irrelevant to the new use are known. In this particular case, D1 discloses the use of captopril in sunscreen compositions for the treatment of photoageing (see claims 1,8 and page 7). As a consequence, captopril is considered to have been disclosed "for improving aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema"

Re Item V.

Reference is made to the following documents:

D1: WO9404129
D2: WO03068141

INDEPENDENT CLAIM 1

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT for the following reasons:

The subject-matter of amended claim 1 is not limited to the "reduction of the visible signs of fine lines on the skin". Rather, the subject-matter of claim 1 is directed to the general idea of "improving aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema". Captopril has been disclosed to protect against photoageing (see D1: claims 1,8 and page 7). Treatment of photoageing, is obviously one way of improving aspects of an individual's skin tone (see also description of the present

application: page 5, third paragraph). The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT.

INDEPENDENT CLAIMS 15 AND 21

For the same reasoning as explained above, D1 also attacks novelty of independent claims 15 and 21.

Furthermore, the subject-matter of claims 15 and 21 cannot be considered new over D2 either. D2 discloses the use of ACE inhibitors to treat the visible signs of ageing such as bag and circles under the eyes (see page 1 and page 2, first paragraph). Therefore claims 15 and 21 also do not meet the requirements of the PCT in respect of novelty (Article 33(2) PCT).

For the assessment of the present claim 21 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment. However, the application of the special approach to the derivation of novelty can only be applied to claims to the use of substances or compositions intended for use in a method referred to in Article 52(4) EPC. The attention of the applicant is drawn to the fact that claim 21 has been construed as a second medical application claim but is directed to a cosmetic use. In the proceedings before the EPO, this approach would not be allowed and the subject-matter of such claim would be interpreted as the "use of an ACE inhibitor and/or angiotensin II receptor antagonist in a composition suitable for improving aspects of an individual's skin tone...". In this sense, claim 1 cannot be considered new over D2.

DEPENDENT CLAIMS 2-14, 16-20, 22

Dependent claims 2-14, 16-20, 22 do not contain any features which, in combination with

the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step (Article 33(2) and (3) PCT).

Claims

1. A cosmetic method for improving aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema,

said method comprising contacting the skin of said individual with a composition comprising at least one ACE inhibitor and/or angiotensin II receptor antagonist, or a cosmeceutically acceptable salt thereof,

wherein said method is for reduction of the visible signs of fine lines on the skin.

2. The cosmetic method according to claim 1, wherein said method is for the reduction of skin ageing.

3. The cosmetic method according to claim 2, wherein said method is for the treatment of wrinkles.

4. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least one ACE inhibitor.

5. The cosmetic method according to claim 4, wherein said ACE inhibitor is a non-thiol-containing ACE inhibitor.

6. The cosmetic method according to any of claims 4-5, wherein said ACE inhibitor is a lipophilic ACE inhibitor

7. The cosmetic method according to any of claims 4-6, wherein said ACE inhibitor is an ACE inhibitor binding the zinc-binding ligand of the active site of ACE via a phosphinyl group or a carboxyl group

8. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least one angiotensin II receptor antagonist.

9. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor is lisinopril, or a cosmeceutically acceptable salt thereof.

10. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least two ACE inhibitor(s) and/or angiotensin II receptor antagonist(s).

11. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.01-100 mg/kg.

12. The cosmetic method according to any of the preceding claims, wherein said composition further comprises a cosmeceutically-acceptable topical carrier.

13. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as a cream or lotion.

14. The cosmetic method according to any of the preceding claims, which comprises repeatedly performing said contacting over an extended period of time.

15. Use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of skin ageing or wrinkling.

16. The use according to claim 15, wherein said skin ageing or wrinkling is considered premature as compared to normal skin ageing and wrinkling.

17. The use according to any claims 15-16 wherein the ACE inhibitor and/or angiotensin II receptor antagonist is according to any of claims 5-9.

18. The use according to any of claims 15-17, wherein the medicament is in a formulation for topical administration to the skin

19. The use according to any of claims 15-18, wherein the medicament is administered at least once daily

20. The use according to any of claims 15-19, wherein the medicament is administered in a concentration equivalent of from 0.01 to 100 mg per kg.

21. Use of an ACE inhibitor and/or angiotensin II receptor antagonist or cosmeceutically acceptable salt thereof for the preparation of a cosmetic composition for use in the improvement of aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema,

wherein said composition is for use in reduction of the visible signs of fine lines on the skin.

22. The use according to claim 21, wherein said improvement and/or maintenance of skin tone comprises reduction of skin ageing and/or wrinkling.

Claims

1. A cosmetic method for improving and/or maintaining aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema,

said method comprising contacting the skin of said individual with a composition comprising at least one ACE inhibitor and/or angiotensin II receptor antagonist, or a cosmeceutically acceptable salt thereof,

with the proviso that if said method is for the prevention of photoageing, then said ACE inhibitor is not captopril.

2. The cosmetic method according to claim 1, wherein said method is for the prevention and/or reduction of skin ageing.

3. The cosmetic method according to claim 2, wherein said method is for the prevention and/or treatment of wrinkles.

4. The cosmetic method according to any of the preceding claims, wherein said method is for reduction of the visible signs of fine lines on the skin.

5. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least one ACE inhibitor.

6. The cosmetic method according to claim 5, wherein said ACE inhibitor is a non-thiol-containing ACE inhibitor.

7. The cosmetic method according to claim 5, wherein said ACE inhibitor is a thiol-containing ACE inhibitor

8. The cosmetic method according to any of claims 5-7, wherein said ACE inhibitor is a lipophilic ACE inhibitor

9. The cosmetic method according to any of claims 5-8, wherein said ACE inhibitor is an ACE inhibitor binding the zinc-binding ligand of the active site of ACE via a phosphinyl group or a carboxyl group

10. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least one angiotensin II receptor antagonist.

11. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is selected from Alacepril, Delapril Benazepril, Cilazapril ,Captopril, Enlapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, Isradipin, perindopril, spirapril, temocapril, Enalapril, losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Zofenapril, Isradipin and Candesartancilexetil, or a cosmeceutically acceptable salt thereof.

12. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is selected from Alacepril, Delapril , Cilazapril ,Benazepril, Captopril, Enlapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, Isradipin, perindopril, spirapril, temocapril, Enalapril, Zofenapril, or a cosmeceutically acceptable salt thereof.

13. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is selected from losartan (Cozaar), valsartan (Diovan), Irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Isradipin, Candesartancilexetil and/or olmesartan medoxomil, or a cosmeceutically acceptable salt thereof.

14. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor is lisinopril, or a cosmeceutically acceptable salt thereof.

15. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least two ACE inhibitor(s) and/or angiotensin II receptor antagonist(s).

16. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.01-100 mg/kg.

17. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.1-10 mg/kg.

18. The cosmetic method according to any of the preceding claims, wherein said composition further comprises a cosmeceutically-acceptable topical carrier.

19. The cosmetic method according to any of the preceding claims, wherein said cosmetic method further comprises one or more of a hormone, plant and/or herbal extracts, moisturizers or humectants, emollients, fragrances, sunscreen actives, anti-wrinkle and/or anti-ageing actives, whitening and/or bleaching actives, sunless tanning actives, preservative and/or antimicrobial actives, anti-acne actives, anti-psoriasis actives, anti-eczema actives, anti-inflammatory actives, vitamin actives, proteins, peptides, amino acids, amino acid derivatives, insect repellants, fungicides, anti-viral agents, anti-cancer agents, anti-hemorrhoid compounds, anti-dandruff compounds, hair-growth stimulating compounds, hair-loss stimulating compounds, nucleic acids, chelating agents, pigments, lipids and/or inorganic salts.

20. The cosmetic method according to any of the preceding claims, wherein said composition further comprises one or more of a hydroxy acid, lactic acid, 2-hydroxy butanoic acid, malic acid, citric acid tartaric acid, decorin-synthesis enhancers, retinoids which include retinol and its esters, retinal, retinoic acid and its derivatives, retinoids, an alpha-hydroxy acid, a beta-hydroxy acid, an alpha-keto acids, a beta-keto acid, a peroxide, a vitamin, an anti-free-radical active agents, selenium, zinc, a beta-carotene, tensioning polymers of natural or synthetic origin, collagen-synthesis enhancers, a matrix metalloproteinase inhibitor, an antioxidant, a collagen modulator, an alpha-hydroxyethanoic acid, a hydroxycaprylic acid; an alpha-

hydroxycarboxylic acid, beta-hydroxycarboxylic acid, a ceramide, a polyhydroxy acid, gamma-linolenic acid, a fruit acid, sugar cane extract, a skin peel agent, or a cosmeceutically-acceptable salt thereof.

21. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as one or more of: a day and/or night and/or hydrating care composition for the face or the body; an anti-wrinkle or anti-ageing composition; a make-up removing composition; a body milk, a sun protective, artificial sun tanning (self-tanning) or after-sun care composition; and/or a face, skin, body or lip makeup product;

22. The cosmetic method according to any of the preceding claims, wherein said composition is formulated in any suitable manner for application to an individual's skin.

23. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as a lotion, cream, face mask, powder, cosmetic patch, ointment, paste, water-based liquid, oil-based liquid or sprayable liquid.

24. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as a cream or lotion.

25. The cosmetic method according to any of the preceding claims, wherein said contacting is conducted at least once daily.

26. The cosmetic method according to any of the preceding claims, wherein said method further comprises contacting the skin with one or more hormones, plant and/or herbal extracts, moisturizers or humectants, emollients, fragrances, sunscreen actives, anti-wrinkle and/or anti-ageing actives, whitening and/or bleaching actives, sunless tanning actives, preservative and/or antimicrobial actives, anti-acne actives, anti-psoriasis actives, anti-eczema actives, anti-inflammatory actives, vitamin actives, proteins, peptides, amino acids, amino aicd derivatives, insect repellants, fungicides, anti-viral agents, anti-cancer agents, anti-hemorrhoid compounds, anti-dandruff compounds, hair-growth stimulating compounds, hair-loss

stimulating compounds, nucleic acids, chelating agents, pigments, lipids and/or inorganic salts.

27. The cosmetic method according to any of the preceding claims, wherein said individual is a post-menopausal, female human being.

28. The cosmetic method according to any of the preceding claims, wherein said individual is a pre-menopausal, female human being.

29. The cosmetic method according to any of the preceding claims, wherein said individual is a male human being.

30. The cosmetic method according to any of the preceding claims, which comprises repeatedly performing said contacting over an extended period of time.

31. Use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of skin ageing or wrinkling.

32. The use according to claim 31, wherein said skin ageing or wrinkling is considered premature as compared to normal skin ageing and wrinkling.

33. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, diabetes mellitus.

34. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, smoking or smoke exposure on skin

35. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by skin photo-ageing processes.

36. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, radiation therapy.

37. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, syndrome X.

38. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, Hutchinson-Gilford progeria.

39. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, Wemers syndrome

40. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, Kindler syndrome.

41. The use according to any of claims 31-32, wherein said skin ageing or wrinkling is caused by, or associated with, corticoid hormone hypersecretion, a vitamin deficiency, administration of glucocorticoids and/or vitamin D and/or derivatives thereof.

42. The use according to any of claims 31-32, wherein the medicament comprises an ACE inhibitor or angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof.

43. The use according to any claims 31-42 wherein the ACE inhibitor and/or angiotensin II receptor antagonist is according to any of claims 2-6

44. The use according to any of claims 31-43, wherein the medicament is in a formulation for topical administration to the skin

45. The use according to any of claims 31-44, wherein the ACE inhibitor/angiotensin II receptor antagonist is formulated as a lotion, powder, cream, ointment, water-based liquid, paste, oil-based liquid, face mask, skin patch or sprayable liquid.

46. The use according to any of claims 31-45 in combination with one or more of a hormones, a plant and/or herbal extracts, a moisturizers or humectants, an emollients, a fragrances, a sunscreen actives, an anti-wrinkle and/or anti-ageing actives, a whitening and/or bleaching actives, a sunless tanning actives, a preservative and/or antimicrobial actives, an anti-acne actives, an anti-psoriasis actives, an anti-eczema actives, an anti-inflammatory actives, a vitamin active, a

protein, a peptide, an amino acid, an amino acid derivative, an insect repellants, a fungicide, an anti-viral agent, an anti-cancer agent, an anti-hemorrhoid compound, an anti-dandruff compound, a hair-growth stimulating compound, a hair-loss stimulating compound, a nucleic acid, a chelating agents, a pigment, a lipid and/or an inorganic salts.

47. The use according to any of claims 31-46, wherein the medicament is administered at least once daily

48. The use according to any of claims 31-47, wherein the medicament is administered at least two times daily.

49. The use according to any of claims 31-48, wherein the medicament is administered in a concentration equivalent of from 0.01 to 100 mg per kg.

50. The use according to any of claims 31-49, wherein the medicament is administered in a concentration equivalent of from 0.1 to 10 mg per kg.

51. Use of an ACE inhibitor and/or angiotensin II receptor antagonist or cosmeceutically acceptable salt thereof for the preparation of a cosmetic composition for use in the improvement and/or maintenance of aspects of an individual's skin tone other than lymphatic drainage, sodium imbalance and local oedema,

with the proviso that if said use is for the prevention of photoageing, then said ACE inhibitor is not captopril.

52. The use according to claim 51, wherein said improvement and/or maintenance of skin tone comprises prevention and/or reduction of skin ageing and/or wrinkling.

53. The use according to claims 51-52, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is according to any of claims 5-15.

54. The use according to any of claims 51-53, wherein said composition comprises more than one ACE inhibitor or angiotensin II receptor antagonist or a cosmeceutically acceptable salt thereof.

55. The use according to any of claims 51-54, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in an amount according to any of claims 16-17.

56. The use according to any of claims 51-55, wherein said cosmetic composition is formulated in a manner according to any of claims 18-24.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

HØIBERG A/S
St. Kongensgade 59 A
DK-1264 Copenhagen K
DANEMARK

Date of mailing *(day/month/year)* 21 February 2005 (21.02.2005)	
Applicant's or agent's file reference P826PC00	**IMPORTANT NOTIFICATION**
International application No. PCT/DK05/000065	International filing date *(day/month/year)* 28 January 2005 (28.01.2005)
International publication date *(day/month/year)*	Priority date *(day/month/year)* 30 January 2004 (30.01.2004)
Applicant Ace ApS et al	

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. *(If applicable)* The **letters "NR"** appearing in the right-hand column denote **a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau** under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

3. *(If applicable)***An asterisk (*)** appearing next to a date of receipt, in the right-hand column, denotes **a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b)** (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
30 January 2004 (30.01.2004)	PA 2004 00136	DK	11 February 2005 (11.02.2005)
16 March 2004 (16.03.2004)	60/553,661	US	NR

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Olaiz Alicia

Facsimile No. +41 22 338 71 30
Telephone No. +41 22 338 9288